Fredag 15 November | 07:16:37 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-10-22 - Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-04-29 - Kvartalsrapport 2025-Q1
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2022-07-14 08:00:00

Vimian Group appoints Carl-Johan Zetterberg Boudrie as new Chief Financial Officer (CFO) and intends to continue to build out its finance organisation to support Vimian’s growth journey. Carl-Johan assumes the position as CFO and member of the Vimian Group management team, and succeeds Henrik Halvorsen who has decided to focus on his role as CFO of Vimian’s Specialty Pharma segment Nextmune.

Carl-Johan Zetterberg Boudrie has extensive experience as CFO in publicly traded companies as well as from senior leadership positions within business development, M&A and management consulting at Beijer Electronics, SEB and Capgemini. The past six years, Carl-Johan held positions as CFO and subsequently CEO of the technology company Doro AB (publ) listed on Nasdaq Stockholm. Most recently, he was CEO of Careium AB (publ), a spin-off from Doro AB.

Carl-Johan Zetterberg Boudrie succeeds Henrik Halvorsen who has held dual positions as CFO of Vimian and CFO of Vimian’s Specialty Pharma segment Nextmune, and who now decided to focus solely on his position at Nextmune.

“I am pleased to welcome Carl-Johan Zetterberg Boudrie as our new CFO. He has a strong background in finance from publicly listed companies and in addition, he brings a wealth of experience in strategy, business development and acquisition growth. He is an experienced and appreciated leader and I am delighted to have him onboard as we continue to build out our finance organisation to support our growth journey. At the same time, I would like to sincerely thank Henrik Halvorsen for his efforts on Vimian level and I respect his decision to focus on Nextmune”, says Fredrik Ullman CEO of Vimian Group.

“I am excited to join the fast-growing and global Vimian Group and become part of a dynamic and entrepreneurial organisation with a great vision to improve animal health”, says Carl-Johan Zetterberg Boudrie, incoming CFO of Vimian Group.

“It has been a privilege to lead the finance team throughout the formation of Vimian and the company’s public listing in June last year. As both Vimian and Nextmune have grown rapidly over the past year, I have decided to focus on my role at Nextmune and look forward to continuing our exciting journey in the global animal health market”, says Henrik Halvorsen, CFO of Vimian Group.

Henrik Halvorsen will remain as Vimian’s CFO until Carl-Johan Zetterberg Boudrie has assumed his position. Carl-Johan will assume the position as CFO of Vimian as soon as a successor has been appointed for his current position.